Clinical Trial Update: A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and efficacy of beclomethasone dipropionate delivered via breath-actuated inhaler in patients aged 12 and older with persistent a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Persistent Asthma

Drugs mentioned

• Beclomethasone Dipropionate (80 and 160 mcg/Day) delivered via Breath-Actuated Inhaler (beclomethasone dipropionate)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Persistent Asthma | Phase 3 | Status: COMPLETED | Results posted: 2017-12-11